C34
Conditions
Interventions
Group 1: Retrospective analysis of cases with NSCLC and SCLC from the diagnosis years 2014-2026
Sponsors
IQVIA Commercial GmbH & Co. OHG
Eligibility
Sex/Gender
All
Age
18 Years to 120 Years
Inclusion criteria
Inclusion criteria: 1. newly diagnosed lung cancer (ICD-10 C34) 2. if diagnosed, place of residence in the federal state of the requested registry (“residence-related cases”) 3. diagnosis years 2014-2026 4. at least one day of survival / close observation time
Exclusion criteria
Exclusion criteria: - the case is known to the registry exclusively on the basis of a. a corpse certificate (DCO cases) b. a pathology report c. a progress report d. a report to the tumor conference e. a combination of the aforementioned notification types - the diagnosis date is unknown - patients who have experienced another cancer up to 5 years before the diagnosis of lung cancer (except for non-melanotic skin tumors, ICD-10 C44)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Characterisation of a real-world cohort of adults with lung cancer (NSCLC or SCLC) diagnosed between 2014 and 2026, and an analysis of their treatment and disease progression. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Description of the demographic and clinical characteristics of adults with lung cancer (for all lung cancer patients, differentiated by NSCLC and SCLC) 2. Development and creation of an algorithm for systemic cancer therapy (SACT; LoT) for patients with NSCLC and SCLC 3. Description of the proportion of patients who commenced treatment, as well as the characteristics of SACT, surgical procedures and radiotherapy (including, but not limited to: treatment intent, type of SACT/surgery received, details of radiotherapy, treatments received following a recurrence, duration of treatment for each treatment line, treatment-free interval, reason for discontinuation of treatment, and any surgical complications) for lung cancer patients overall and differentiated by NSCLC and SCLC 4. Description of the chronological sequence of ‘lines of treatment’ (LoT) for all lung cancer patients up to and including the 4th LoT, differentiated by NSCLC and SCLC 5. Description of overall survival (OS) from the date of diagnosis, differentiated by NSCLC and SCLC 6. Description of overall survival (OS) from the start of the 1st, 2nd, 3rd and 4th LoT, differentiated by NSCLC and SCLC 7. Description of progression-free survival (PFS) from the start of the 1st, 2nd, 3rd and 4th LoT, broken down by NSCLC and SCLC 8. Description of time to next treatment from the start ( TTNT) from the start of the 1st, 2nd, 3rd and 4th LoT, differentiated by NSCLC and SCLC 9. Description of time to next treatment or death (TTNTD) from the start of the 1st, 2nd, 3rd and 4th LoT, differentiated by NSCLC and SCLC 10. Description of the overall response to treatment and response rates, i.e. the number and proportion of patients who achieved complete or partial remission, those who experienced recurrence, those in whom the disease progressed or who suffered a relapse, as well as a description of the patterns of metastasis, differentiated by NSCLC and SCLC 11. Descripti | — |
Countries
Germany
Contacts
Public ContactAnnika Waldmann
Universität zu Lübeck, Institut für Sozialmedizin und Epidemiologie
Outcome results
None listed